Table 2 Comparison of clinical manifestations and laboratory features between SLC22A3 hypomethylated and hypermethylated MDS patients
From: SLC22A3 methylation-mediated gene silencing predicts adverse prognosis in acute myeloid leukemia
Patient’s parameter | Hypomethylated (n = 38) | Hypermethylated (n = 10) | P value |
|---|---|---|---|
Sex (male/female) | 20/18 | 8/2 | 0.304 |
Age (years) | 57 (27–83) | 67 (28–84) | 0.454 |
WBC (× 109/L) | 4.0 (1.2–82.4) | 4.4 (1.2–19) | 0.493 |
HB (g/L) | 61 (35–140) | 62 (46–107) | 0.493 |
PLT (× 109/L) | 61 (0–1176) | 56 (12–323) | 0.919 |
BM blasts (%) | 5 (0–19) | 6 (0–17) | 0.648 |
WHO classification | 0.268 | ||
MDS-SLD/MLD | 13 | 3 | |
MDS-RS | 7 | 0 | |
MDS with isolated del(5q) | 1 | 0 | |
MDS-EB1 | 5 | 4 | |
MDS-EB2 | 12 | 3 | |
Cytogenetic classification | 1.000 | ||
Favorable | 23 (60%) | 7 (70%) | |
Intermediate | 6 (16%) | 1 (10%) | |
Adverse | 6 (16%) | 1 (10%) | |
No data | 3 (8%) | 1 (10%) | |
IPSS | 0.476 | ||
Low | 6 (16%) | 0 (0%) | |
Int-1 | 15 (39%) | 7 (70%) | |
Int-2 | 9 (24%) | 1 (10%) | |
High | 5 (13%) | 1 (10%) | |
No data | 3 (8%) | 1 (10%) | |
Gene mutations | |||
CEBPA ( ±) | 0/31 | 0/10 | |
IDH1/2 ( ±) | 1/30 | 0/10 | 1.000 |
DNMT3A ( ±) | 0/31 | 0/10 | |
U2AF1 ( ±) | 1/30 | 1/9 | 0.433 |
SF3B1 ( ±) | 4/27 | 0/10 | 0.556 |
SRSF2 ( ±) | 0/31 | 2/8 | 0.055 |
SETBP1 ( ±) | 1/30 | 0/10 | 1.000 |